- Home
- CHW vs ABSI Comparison
CHW vs ABSI Comparison
Compare CHW & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.60
Company Overview
Basic Information| Metric | CHW | ABSI |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.9M | 577.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHW | ABSI |
|---|---|---|
| Price | $8.08 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.98 |
| AVG Volume (30 Days) | 195.2K | ★ 3.2M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | ★ 9.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,815,000.00 |
| Revenue This Year | N/A | $10.72 |
| Revenue Next Year | N/A | $313.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.07 | $2.01 |
| 52 Week High | $6.54 | $6.33 |
Technical Indicators
Market Signals| Indicator | CHW | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 41.93 |
| Support Level | $7.86 | $2.40 |
| Resistance Level | $8.27 | $2.83 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 58.54 | 32.69 |
Price Performance
Historical Comparison CHW
ABSI
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.